Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
email:
Poppy.Holland@gla.systa-s.com
Hospital Palliative Care Team, Queen Elizabeth University Hopsital, 1345 Govan Road, Glasgow, G51 4TF
Tate, M. et al. (2025) Clinical effectiveness, safety and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomised, phase III trial. Antimicrobial Agents and Chemotherapy, 69(8), e0005425. (doi: 10.1128/aac.00054-25) (PMID:40552814)
Tate, M. et al. (2025) Clinical effectiveness, safety and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomised, phase III trial. Antimicrobial Agents and Chemotherapy, 69(8), e0005425. (doi: 10.1128/aac.00054-25) (PMID:40552814)
